Analysis of LMP and TAP polymorphisms by polymerase chain reaction-restriction fragment length polymorphism in rheumatoid arthritis

J Vinasco, A Fraile, A Nieto, Y Beraun, E Pareja, L Mataran, J Martín

Objective—The aim of this study was to investigate the relation between the polymorphism of large molecular weight proteasome (LMP) (LMP2-LMP7) and transporter associated with antigen processing (TAP) (TAP1-TAP2) genes and rheumatoid arthritis (RA).

Methods—Sixty RA patients and 102 ethnically matched unrelated healthy subjects were typed for LMP, TAP, and disease associated HLA-DRB1 alleles by using a new strategy based on polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) with amplification created restriction sites.

Results—The polymorphism of LMP (LMP2-LMP7) and TAP (TAP1-TAP2) genes was examined in shared epitope positive and negative RA patients and controls. No significant differences in the LMP or TAP allele frequencies were observed between the total patient and control groups or the patients and controls positive or negative for the shared epitope.

Conclusion—The data suggest that the polymorphisms of LMP and TAP genes do not have an important influence in the pathogenesis of RA, although larger studies will be needed to provide more conclusive evidence on the role of these genes in RA. A new, highly reliable strategy for typing LMP alleles is also described.

Methods

Subjects
Sixty patients with RA and 102 ethnically matched control individuals, who had been previously defined for HLA-DR disease associated alleles (-DR1,-DR4, and -DR10), were included in this study. Clinical and laboratory characteristics of these patients have been described in a previous publication; they included: age at disease onset, mean disease duration, presence of rheumatoid nodules, presence of additional extra-articular manifestations, which included vasculitis and lung disease, and rheumatoid factor seropositivity.
The bi-allelic polymorphism at codon 60 (Arg-His) in the LMP2 gene was analysed by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method using as primers LMP2X (forward) and LMP2Y (reverse), which amplify a 228 bp fragment. The variant 60-Arg was typed for the presence of a restriction site for CfoI, as described previously.14 The variant 60-His can be detected by the location of a restriction site for Alw21I. However, at eight bases 3' to this position we found a second recognition site for Alw21I, which is present in both alleles; therefore it could not be used for 60-His typing. To avoid this problem a modified primer was designed (LMP2Y), which destroys the shared Alw21I site, leaving intact the polymorphic site 60-His (fig 1A).

A recently described polymorphism at codon 145 (Lys-Gln) of the second exon in the LMP7 gene was also analysed by PCR-RFLP. A fragment of 193 bp, that contains the LMP7 polymorphic site, was amplified using as primers LMP7X (forward) and LMP7Y (reverse). Variant 145-Gln lies in a restriction site for BsmI. To analyse the variant 145-Lys, a modified primer (LMP7Y), was designed to create a restriction site for HindIII (fig 1B).

Genomic DNA was extracted from whole blood using a standard phenol/chloroform extraction before proteinase K digestion. DNA was amplified in 50 µl reaction mixtures containing 0.2–0.5 µg of genomic DNA using two units of thermostable DNA polymerase (DyNAzyme II) in the supplied 1 x reaction buffer. Cycling conditions were as follows: 94°C for five minutes; 30 cycles of 94°C for one minute, 57°C of annealing temperature for 50 seconds in LMP2 amplifications and 62°C for 45 seconds in LMP7, 72°C for one minute; 72°C for 10 minutes. The amplified fragments were digested with the discriminating restriction enzymes for two to four hours. Cleavage of amplified fragments was detected by electrophoresis in 4% agarose gel (3% NuSieve, 1% SeaKem. FMC, Rockland, ME, USA.)

### HLA-DR4 and -DR1 Subtyping, TAP1 and TAP2 Genotyping

DRB1*04 and DRB*01 subtyping was performed by the “allele walking” strategy. Typing for TAP alleles was performed using a method based on PCR-RFLP with amplification created restriction sites.

### Statistical Analysis

The significance level (p) was obtained by using the χ² test or by Fisher’s exact test, when appropriate. The p value was corrected (pc) by use of the Bonferroni inequality method.

### Results

The patients and controls were stratified in relation to positivity or negativity to shared epitope to minimise the possible linkage disequilibria between DRB1 and LMP or TAP...
Polymorphism of LMP and TAP genes and RA


**Discussion**

In this study we describe a new strategy, based on PCR double RFLP with amplification created restriction sites, for LMP2 and LMP7 typing. This strategy, along with the previously designed one to type TAP alleles, was applied to identify LMP and TAP genotypes in our population. We found that PCR-RFLP with amplification created restriction sites a favourable alternative to the several methods previously used to identify LMP and TAP polymorphisms. The most used typing methods, PCR-SSO and PRC-SSP depend on the differential hybridisation of short stretches of DNA, therefore the possibility of false positive or negative is possible when the conditions are not carefully adjusted. The strategy we designed has several advantages: restriction analysis is a potent tool to detect polymorphism, making false positive results very unlikely. Only positive results are taken into account to assign an allele, this is why the two variants at each polymorphic residue are assayed; the two results obtained must be congruent within themselves, in this way false negatives are practically avoided and the homozygosity of the sample tested unequivocally established. The use of amplification created restriction sites makes it possible to create or eliminate a restriction site when a natural variant is not available or informative. Consequently, the results obtained for LMP and TAP alleles allows the totally reliable assignment of the genotypes of the samples studied. As in other typing methods using genomic DNA, it was not possible to assign TAP1 and TAP2

---

**Table 1** LMP2 and LMP7 genotype frequencies in RA patients and normal controls

<table>
<thead>
<tr>
<th>LMP genotypes</th>
<th>Patients (n=60) n (%)</th>
<th>Controls (n=102) n (%)</th>
<th>Patients (n=35) n (%)</th>
<th>Controls (n=66) n (%)</th>
<th>Patients (n=25) n (%)</th>
<th>Controls (n=58) n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>LMP2-R/R</td>
<td>35 (58)</td>
<td>56 (55)</td>
<td>20 (57)</td>
<td>29 (66)</td>
<td>15 (60)</td>
<td>27 (46.5)</td>
</tr>
<tr>
<td>LMP2-H/H</td>
<td>1 (2)</td>
<td>3 (3)</td>
<td>1 (2)</td>
<td>0</td>
<td>0</td>
<td>3 (5.2)</td>
</tr>
<tr>
<td>LMP2-R/H</td>
<td>24 (40)</td>
<td>43 (42)</td>
<td>14 (40)</td>
<td>15 (34)</td>
<td>10 (40)</td>
<td>28 (48.3)</td>
</tr>
<tr>
<td>LMP7-Q/Q</td>
<td>48 (80)</td>
<td>91 (89)</td>
<td>28 (80)</td>
<td>36 (81.8)</td>
<td>20 (80)</td>
<td>55 (94.8)</td>
</tr>
<tr>
<td>LMP7-K/K</td>
<td>2 (3)</td>
<td>3 (3)</td>
<td>1 (3)</td>
<td>3 (6.8)</td>
<td>1 (4)</td>
<td>0</td>
</tr>
<tr>
<td>LMP7-Q/K</td>
<td>10 (17)</td>
<td>8 (8)</td>
<td>6 (17)</td>
<td>5 (11.4)</td>
<td>4 (16)</td>
<td>3 (5.2)</td>
</tr>
</tbody>
</table>

**Table 2** TAP1 and TAP2 genotype frequencies in RA patients and normal controls

<table>
<thead>
<tr>
<th>LMP genotypes</th>
<th>Patients (n=66) n (%)</th>
<th>Controls (n=61) n (%)</th>
<th>Patients (n=35) n (%)</th>
<th>Controls (n=28) n (%)</th>
<th>Patients (n=25) n (%)</th>
<th>Controls (n=33) n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>LMP2-R/R</td>
<td>35 (58)</td>
<td>56 (55)</td>
<td>20 (57)</td>
<td>29 (66)</td>
<td>15 (60)</td>
<td>27 (46.5)</td>
</tr>
<tr>
<td>LMP2-H/H</td>
<td>1 (2)</td>
<td>3 (3)</td>
<td>1 (2)</td>
<td>0</td>
<td>0</td>
<td>3 (5.2)</td>
</tr>
<tr>
<td>LMP2-R/H</td>
<td>24 (40)</td>
<td>43 (42)</td>
<td>14 (40)</td>
<td>15 (34)</td>
<td>10 (40)</td>
<td>28 (48.3)</td>
</tr>
<tr>
<td>LMP7-Q/Q</td>
<td>48 (80)</td>
<td>91 (89)</td>
<td>28 (80)</td>
<td>36 (81.8)</td>
<td>20 (80)</td>
<td>55 (94.8)</td>
</tr>
<tr>
<td>LMP7-K/K</td>
<td>2 (3)</td>
<td>3 (3)</td>
<td>1 (3)</td>
<td>3 (6.8)</td>
<td>1 (4)</td>
<td>0</td>
</tr>
<tr>
<td>LMP7-Q/K</td>
<td>10 (17)</td>
<td>8 (8)</td>
<td>6 (17)</td>
<td>5 (11.4)</td>
<td>4 (16)</td>
<td>3 (5.2)</td>
</tr>
</tbody>
</table>

**Table 2** summarises the distribution of TAP genotype frequencies in RA patients and controls. As in other typing methods, the assignment of TAP1 and TAP2 genotypes in some heterozygotes was not possible because each dimorphic residue is analysed individually. No statistically significant differences were observed in the comparison of TAP1 and TAP2 genotype distribution between the patients with RA and the healthy controls. Again, no significant differences in the TAP1 and TAP2 genotype frequencies were observed between the patients positive or negative for the shared epitope and shared epitope matched healthy controls.
alleles in people heterozygous at two or more polymorphic sites. To circumvent this problem we are currently analysing the possibility of applying the allele walking strategy on cDNA samples.

The location of polymorphic LMP and TAP genes in the HLA class II region and their function in antigen processing raises the question of the relation between the polymorphism of these genes and RA. It is interesting to note that a substitution in mouse LMP2 (Arg → His₁₈) is identical both in position and identity of the substituted residues observed in human LMP2 and that preliminary findings suggest that this structural polymorphism may have functional consequences. We have not found any evidence of association between polymorphism in LMP2 and LMP7 genes and RA. In agreement with our present result, a previous study has failed to find an association between LMP polymorphism and RA. Thus, it is unlikely that LMP genes are significantly associated with RA, although further studies with larger numbers of patients are needed to confirm this. In addition to the previous study we have analysed our patient and control groups in relation to positivity or negativity of the shared epitope. Our negative findings are in contrast with previous work describing an association between LMP polymorphism and other autoimmune disease.

Although no naturally occurring mutations in human TAP genes leading to a changed peptide transport specificity have been described so far, a recent study has shown that a single point mutation generated by site directed mutagenesis in TAP2 gene was sufficient to change the peptide transport specificity. The recently described variations in TAP1 (codon 648) and TAP2 (codon 651), which have not been studied in relation to their selectivity of transport, may have functional significance. This is the first report concerning an association between TAP genes, which includes the polymorphisms at codons 333-637-648 of TAP1 and at codons 379-565-651-665-687 of TAP2 and RA. Our analysis of the genetic polymorphism in the TAP genes in RA patients and healthy controls indicates that there was no association between TAP polymorphism and RA. Although several studies have analysed the association of TAP genes with RA, these reports have been limited to TAP1 and they did not analyse the recently described polymorphism in TAP1 (codon 648) and TAP2 (codon 651). Our data confirm and extend the previous reports where no primary association between TAP alleles and RA was seen in different populations.

LMP and TAP genes could be modulating not susceptibility to RA but disease severity. Therefore, we examined the relation of LMP and TAP genotypes with clinical and laboratory parameters. Our preliminary data do not suggest a significant association of LMP2-LMP7 or TAP1-TAP2 genotypes with any of these characteristics (data not shown). On the other hand, it would be possible, as recently proposed in AIDS, that combinations of HLA and TAP alleles may be important in the course of RA. Sample sizes must be larger than that used in this study, to convincingly evaluate the influence of these genes either individually or as extended haplotypes in the pathogenesis of RA.

In conclusion, the distribution of LMP2, LMP7, TAP1, and TAP2 alleles was determined using a new strategy we designed, based on PCR-RFLP and amplification created restriction sites, on patients with RA and controls. These results seem to rule out the relevance of LMP and TAP polymorphism in the pathogenesis of RA, although larger studies will be needed to provide more conclusive evidence on the role of these genes in RA.

This work was supported by SAF93-028 and SAF97-0046 grants from Plan Nacional de I+D (CICYT), a fellowship from FIS nº95/533. We thank C Oloriz for technical assistance and M Angel Lopez-Nevot for his support.

21 Deng Y, Muir A, Macalren NK, She JX. Association of LMP2 and LMP7 genes within the major histocompati-
Polymorphism of LMP and TAP genes and RA


Analysis of LMP and TAP polymorphisms by polymerase chain reaction-restriction fragment length polymorphism in rheumatoid arthritis

J Vinasco, A Fraile, A Nieto, Y Beraun, E Pareja, L Mataran and J Martín

doi: 10.1136/ard.57.1.33

Updated information and services can be found at:
http://ard.bmj.com/content/57/1/33

These include:

References
This article cites 27 articles, 4 of which you can access for free at:
http://ard.bmj.com/content/57/1/33#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

Genetics (968)
Immunology (including allergy) (5144)
Connective tissue disease (4253)
Degenerative joint disease (4641)
Musculoskeletal syndromes (4951)
Rheumatoid arthritis (3258)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/